UK Firms Lead As EU Biotechs Complete Best Ever 1Q VC Fundraising
This article was originally published in Scrip
Executive Summary
Europe's biotech sector has just registered its best ever 1Q fundraising from venture capital sources. While the opportunities for conducting initial public offerings have all but dried up, European biotechs announced VC commitments of more than $600m – almost double the amount raised in the equivalent quarter in 2015 – with UK firms taking three of the top 10 slots.
You may also be interested in...
Iterum Therapeutics Focused On First Oral Penem
Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.